Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efbemalenograstim Alfa for Prevention of Neutropenia in Ovarian and Cervical Cancer
NCT06251947Phase 2Recruiting
- Sponsor
- Shandong University
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efbemalenograstim alfa in febrile neutropenia (FN) and neutropenia, sponsored by Shandong University. Primary endpoint: Incidence of grade 3/4 neutropenia. Started Apr 2024; status: recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
febrile neutropenia (FN)neutropenia
Beyond the preview
Go deeper on NCT06251947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251947.